Curriculum Vitae - College of Pharmacy - Nova Southeastern ...

A. LYMPEROPOULOS-CV
Curriculum Vitae
Education/Training:
1) Post Doctoral Research Fellow in Molecular Cardiovascular Biology/Medicine, Thomas
Jefferson University, Philadelphia, PA (09/2004 –07/2009)
2) Ph.D. in Pharmacology, University of Patras, Patras, Greece (03/2000 - 02/2004)
3) M.Sc. in “Medicinal Chemistry: Drug Design & Development”, University of Patras, Patras,
Greece (10/1998 - 03/2000)
4) B.Sc. in Pharmacy, University of Patras, Patras, Greece (10/1993 - 07/1998)
Positions/Employment, Memberships and Honors:
August 2009-Present: Assistant Professor of Pharmacology, Dept. of Pharmaceutical Sciences,
College of Pharmacy, Nova Southeastern University, Davie/Ft. Lauderdale, FL.
Duties: Teaching, Research, Administration.
Research focus: Biology and regulation of G-protein coupled receptors (GPCRs), such as
adrenergic receptors and receptors for angiotensin II, in the pathophysiology of heart failure
and, more broadly, in the neurohormonal control of the circulation. The main goal is discovery
of new and innovative drugs for countering the cardio-toxic actions of catecholamines and of
angiotensin II (and also of other hormones) in heart failure. Particular focus is given on the role
of these receptors in adrenal gland function in relation with the cardiovascular system, thus
providing clues for new treatments for cardiovascular disease. The research utilizes cutting-edge
in vivo gene therapy techniques to manipulate, for therapeutic purposes, various GPCR kinases
(GRKs) and beta-arrestins, proteins that normally desensitize receptors (among other functions)
and are involved in heart failure pathophysiology.
August 2004-July 2009: PostDoctoral Research Fellow, Center for Translational
Medicine, Thomas Jefferson University, Philadelphia, PA.
Mentor: Dr. Walter J. Koch
Research focus: Cardiovascular biology/pharmacology and gene therapy, with a particular
interest in mechanisms of adrenergic system regulation in heart failure and in ways of
manipulating these mechanisms for therapeutic purposes. In particular, novel roles of G-protein
1

A. LYMPEROPOULOS-CV
coupled receptor kinases and their co-factors, beta-arrestins, in regulation of various important
cardiovascular G-protein coupled receptors are investigated.
November 1998-November 2003: Graduate Research Assistant, Department of
Pharmacology, School of Medicine, University of Patras, Patras, Greece
Mentor: Dr. Chris S. Flordellis
Doctorate thesis project: Study of signal transduction from wild-type and polymorphic
human α 2 -adrenergic receptors.
July 1997-August 1997: Visiting Undergraduate Lab Assistant, Department of Cell Biology, John
Innes Centre, Norwich Research Park, England, UK
Mentor: Dr. Liam Dolan
Research objective: Additional training in molecular biology techniques.
November 1997-September 1998: Undergraduate Lab Assistant, Department of Molecular
Biology, University of Patras Medical School, Patras, Greece
Mentors: Dr. Ioannis Zarkadis, Dr. Georgia Sotiropoulou
Research project: Training in basic molecular biology techniques.
Teaching Experience:
2009-Present: Assistant Professor, Teaching undergraduate students of the PharmD
Program and postgraduate students of the PhD program of the Nova Southeastern
University`s College of Pharmacy.
Specifically:
Course Coordinator of the elective course “Individualized Pharmacotherapy” of the
PharmD Program curriculum and of the core course “Applied Pharmacology” of the
PhD Program curriculum.
Instructor in core courses “Pharmacodynamics IV & V” of the PharmD Program
curriculum and in core course “Molecular and Cellular Pharmacodynamics” of the
PhD Program curriculum.
Guest Lecturer in core course “Molecular Medicine & Pharmacogenomics” of the
PhD Program curriculum and in elective course “Molecular Medicine” of the PharmD
Program curriculum.
2003: Guest Lecturer, Special Topics in Molecular Pharmacology and Biology,
Graduate Courses Program in the “Basic Medical Sciences”, School of Medicine,
University of Patras, Patras, Greece.
2

A. LYMPEROPOULOS-CV
1999: Adjunct instructor, Techniques in Molecular Pharmacology, Department of
Pharmacology, School of Medicine, University of Patras, Patras, Greece.
Professional Associations:
American Heart Association, Premium Professional Member of the “Basic Cardiovascular
Sciences (BCVS)” & the “Functional Genomics & Translational Biology” councils, since 2006.
Heart Failure Society of America, Full Member at the early career/junior faculty level, since
2007.
American Association for the Advancement of Science (AAAS), member since February 2005.
New York Academy of Sciences, member since October 2005.
American Association of Colleges of Pharmacy (AACP), member since July 2008.
American Chemical Society, member since April 2007.
Greek Society of Pharmacology, member since March 2001.
Greek Association of Pharmacists, member since February 2001.
Greek Society of Biochemistry and Molecular Biology, member since June 1999.
Honors and Awards:
• November 12, 2011: Elected Fellow of the American Heart Association (FAHA) with its
“Council on Basic Cardiovascular Sciences (BCVS)”
• Recipient of AHA Scientist Development Grant (SDG) Award (National Center) entitled:
“Role of adrenal beta-arrestin-1 in angiotensin II-induced aldosterone production in postinfarct
heart failure” (Award ID: 09SDG2010138), Principal Investigator: A. Lymperopoulos,
PhD, Duration: 07/01/2009-06/30/2014, Gross Annual Funding: $77,000 USD
• 2006 Melvin L. Marcus Young Investigator Award in Cardiovascular Sciences Finalist,
“Adrenal G-protein coupled Receptor Kinase 2 Up-regulation Mediates Sympathetic
Overstimulation in Chronic Heart Failure”, American Heart Association Scientific Sessions
2006, Chicago, IL,12-15 November 2006
• 2010 Cardiovascular Research Award of the Council on Basic Cardiovascular Sciences of
the European Society of Cardiology (ESC) Finalist, “Genetic deletion of β-arrestin-1
improves function of the infarcted heart by reducing cardiac β-adrenergic receptor
desensitization and cardiotoxic neurohormonal overstimulation”, Frontiers in
3

A. LYMPEROPOULOS-CV
Cardiovascular Biology Congress of the ESC Council on Basic Cardiovascular Sciences, Berlin,
Germany, 16-19 July 2010
• AHA Great Rivers (Formerly: Pennsylvania-Delaware) affiliate Post Doctoral Fellowship
award Recipient (July 2005-June 2007)
• AHA Great Rivers (Formerly: Pennsylvania-Delaware) affiliate Post Doctoral Fellowship
award Recipient (One-year extension of above fellowship: July 2007-June 2008).
Application received average priority score of 1.2778 (best possible: 1.0) and its percentile
rank was 0.76 (best possible: 0.01)
• 1st best oral presentation award winner at the 3rd Jefferson Postdoctoral Research
symposium, held at Thomas Jefferson University, Philadelphia, PA, USA (24 June 2008)
• 1st best poster presentation award winner at the 1st Jefferson Postdoctoral Research
symposium, held at Thomas Jefferson University, Philadelphia, PA, USA (15 May 2006)
• Research Abstract entitled: “Biased Agonism/Antagonism of β-arrestin Activation by the
Angiotensin II Type 1 Receptor: a Study of Sartans and Angiotensin II Analogs Using
Aldosterone Turnover as a Readout” selected for special honorary presentation at the
“Best of AHA Specialty Conferences Poster Session: BCVS 2010”, November 15, 2010,
2010 AHA Scientific Sessions, Chicago, IL, USA, as being a top-scoring abstract (among the
top 10 percent of the accepted abstracts for that meeting)
• Award for top of class graduating in the “M.Sc. in Medicinal Chemistry” post-graduate
studies program Recipient, University of Patras, Patras, Greece (Class 2000)
• Peer reviewer for the American Heart Association`s (AHA) Basic Cardiovascular Sciences
(BCVS) council, both for scientific research grants submitted to AHA for funding and for
scientific abstracts submitted to AHA Scientific Sessions
• New Investigator Award (NIA) research grant peer reviewer for the American Association
of Colleges of Pharmacy (AACP)
• Research grant peer reviewer for the South African Medical Research Council (MRC)
• Undergraduate student fellowship recipient for participation in the “Pharmacy Student
Professional Training Program”, funded by the European Union Peripheral Development
Support Framework, Scientific Research and Development Support Program II, 1997-1998
• Graduate student fellowship recipient, European Union Peripheral Development Support
Framework, Scientific Research and Development Support Program II, 1998-2000
• Research fellowship recipient, BIOMED II Program, European Union Research Council,
1998-2001
4

A. LYMPEROPOULOS-CV
• NATO/FEBS travel/participation grant award recipient, NATO/FEBS Advanced Study
Institute-International Summer School on «Molecular Mechanisms of Signal Transduction»,
Island of Spetsai, Greece, 1999
• HFSA Travel grant award recipient for participation at the 12th HFSA Annual Scientific
Meeting, held in Toronto, Ontario, Canada, 21-24 September 2008
• EMBO young scientist travel grant award recipient for participation in the EMBO Practical
Course: “Advanced Techniques in Molecular Medicine”, organized by the Departments of
Medical Sciences, and of Genetics and Pathology, Uppsala University, Uppsala, Sweden,
2002
Scholarly and Editorialist Honors and Activities:
1) Associate Editor of “Pharmacology Research & Perspectives”, a peer-reviewed journal
of the British Pharmacological Society, & Academic Editor of “Medicine”, a peerreviewed
medical journal of the esteemed publisher Wolters Kluwer Health.
2) Member of the Editorial Boards of the following peer-reviewed journals: “International
Journal of Hematology Research” (since November 2014); “Heart Health” (since
September 2014); “International Archives of Clinical Pharmacology” (since November
2014); “Journal of Pharmacology and Pharmacovigilance” (since November 2014);
“Toxicology and Allied Clinical Pharmacology” (since August 2014); “Chronic Diseases-
International” (since August 2014); “Journal of Pharmacology & Pharmacogenomics”
(since August 2014); “Journal of Addiction and Neuropharmacology” (since May 2014);
“International Journal of Biochemistry Research & Review” (since April 2014); “Journal
of Clinical Immunology and Immunotherapy” (since March 2014); “Journal of
Endocrine System and Enzymology” (since August 2014); “Case Reports in Internal
Medicine” (since December 2013); “World Journal of Cardiology” (since November
2013); “World Journal of Biological Chemistry” (since November 2013); “Journal of
Geriatric Cardiology” (since December 2013); “Journal of Cardiology and Therapy”
(since October 2013); “Austin Journal of Pharmacology and Therapeutics” (since
October 2013); “Journal of Clinical and Laboratory Investigation Updates” (since June
2013); “Journal of Pharmacogenomics and Pharmacoproteomics” (since January 2013);
“American Journal of Life Sciences” (since December 2012); “American Journal of
Cardiovascular Disease” (since March 2011); “Journal of Carcinogenesis and
Mutagenesis” (since July 2010); and “International Journal of Cancer Studies &
Research (IJCR)” (since May 2012).
3) Scientific manuscript reviewer for the following peer-reviewed journals: “Journal of
Biological Chemistry”, “British Journal of Pharmacology”, “Circulation Research”,
“Pharmacogenomics”, “American Journal of Cardiology”, “Hypertension”, “European
Journal of Biophysics”, “Scientific Reports”, “Molecular Basis of Disease”, “American
Heart Journal”, “International Journal of Molecular Sciences”, “Drug Design,
Development and Therapy”.
5

A. LYMPEROPOULOS-CV
4) Chapter/book peer-reviewer for the pharmacological textbooks/pharmaceutical
monographs: “Remington: The Science and Practice of Pharmacy” (22 nd edition, 2012) &
“Remington Education: Pharmaceutics” (Author: Shelley Chambers Fox, scheduled for
publication in 2013), both by publisher: “Pharmaceutical Press”, Philadelphia, PA, USA.
Patents:
1) Provisional patent entitled: “Adrenal GRK2 Activity as a Therapeutic Target for
Heart Failure”, Patent ID: KOC_WAL.001, Inventors: Dr. Lymperopoulos, A.,
and Dr. Koch, W.J. Filed with the “Office of Technology Transfer”, Thomas
Jefferson University, Philadelphia, PA, 19107, USA. Granted on 01/12/2007,
present status: active.
2) Provisional patent entitled: “Therapeutic strategies for lowering aldosterone levels
post-myocardial infarction and in heart failure”. U.S. Provisional Patent
Application #61/389,819. Inventors: Dr. Lymperopoulos, A., and Dr. Koch, W.J.
Filed by the “Office of Technology Transfer”, Nova Southeastern University, Fort
Lauderdale, FL 33314, USA, on 10/05/2010.
Peer-reviewed Publications:
1) Bathgate-Siryk, A., Dabul, S., Pandya, K., Walklett, K., Rengo, G., Cannavo, A.,
De Lucia, C., Liccardo, D., Gao, E., Leosco, D., Koch, W.J., Lymperopoulos, A.
Negative Impact of β-Arrestin-1 on Post-Myocardial Infarction Heart Failure via
Cardiac and Adrenal-Dependent Neurohormonal Mechanisms. Hypertension. 63:
404-412 (2014).
2) Lymperopoulos, A., Garcia, D., Walklett, K. Pharmacogenetics of cardiac
inotropy. Pharmacogenomics 15: 1807-1821 (2014). Review.
3) Drosatos, K., Lymperopoulos, A., Kennel, P.J., Pollak, N., Schulze, P.C.,
Goldberg, I.J. Pathophysiology of Sepsis-Related Cardiac Dysfunction: Driven by
Inflammation, Energy Mismanagement, or Both Curr. Heart Fail. Rep. 2014 Dec
5. [Epub ahead of print]. Invited Review.
4) Lymperopoulos, A., French, F. Pharmacogenomics of heart failure. Methods Mol.
Biol. 1175: 245-257 (2014). Invited Book Chapter.
5) Lymperopoulos, A., Negussie, S. βArrestins in Cardiac G Protein-Coupled
Receptor Signaling and Function: Partners in Crime or "Good Cop, Bad Cop" Int.
J. Mol. Sci. 14: 24726-24741 (2013). Review.
6

A. LYMPEROPOULOS-CV
6) Salazar, N.C., Vallejos, X., Siryk, A., Rengo, G., Cannavo, A., Liccardo, D., De Lucia, C., Gao,
E., Leosco, D., Koch, W.J., Lymperopoulos, A. GRK2 blockade with betaARKct is essential
for cardiac beta2-adrenergic receptor signaling towards increased contractility. Cell
Commun. Signal. 11: 64 (2013)
7) Lymperopoulos, A., Rengo, G., Koch, W.J. Adrenergic Nervous System in Heart Failure:
Pathophysiology and Therapy. Circ. Res. 113: 739-753 (2013). Invited Review.
8) Siryk-Bathgate, A., Dabul, S., Lymperopoulos, A. Current and future G protein-coupled
receptor signaling targets for heart failure therapy. Drug Des. Devel. Ther. 7: 1209-1222
(2013). Invited Review.
9) Lymperopoulos, A., Bathgate, A. Arrestins in the cardiovascular system. Prog. Mol. Biol.
Transl. Sci. 118: 297-334 (2013). Invited Book Chapter.
10) Lymperopoulos, A., Negussie, S., Walklett, K. Research Highlights: Adrenergic receptor
pharmacogenetics in heart failure. Pharmacogenomics. 14: 1545-1549 (2013). Invited
“Research Highlights” article.
11) Lymperopoulos, A. Physiology and pharmacology of the cardiovascular adrenergic system.
Front. Physiol. 4: 240 (2013). Invited Review.
12) Lymperopoulos, A., Bathgate, A. Pharmacogenomics of the heptahelical receptor
regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown.
Pharmacogenomics 13: 323-341 (2012). Review.
13) Lymperopoulos, A. Ischemic Emergency: Endothelial Cells Have Their Own "Adrenaline
Shot" at Hand. Hypertension 60: 12-14 (2012). Invited editorial commentary.
14) Rengo, G., Lymperopoulos, A., Zincarelli, C., Femminella, G.D., Liccardo, D., Pagano, G., de
Lucia, C., Cannavo, A., Gargiulo, P., Ferrara, N., Perrone Filardi, P., Koch, W.J., Leosco, D.
Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptorcatecholamine
production axis in heart failure. Br. J. Pharmacol. 166: 2430-2440 (2012)
15) Rengo, G., Zincarelli, C., Femminella, G.D., Liccardo, D., Pagano, G., de Lucia, C., Altobelli,
G.G., Cimini, V., Ruggiero, D., Perrone-Filardi, P., Gao, E., Ferrara, N., Lymperopoulos, A.,
Koch, W.J., Leosco, D. Myocardial β(2)-adrenergic receptor gene delivery promotes
coordinated cardiac adaptive remodeling and angiogenesis in heart failure. Br. J.
Pharmacol. 166: 2348-2361 (2012)
7

A. LYMPEROPOULOS-CV
16) Ansari, R.A., Rizvi, S.A., Husain, K., Lymperopoulos, A., Berndt, W.O. Effect of sulfhydryl
modification on rat kidney basolateral plasma membrane transport function. Bull. Environ.
Contam. Toxicol. 89: 699-703 (2012)
17) Rengo, G., Perrone-Filardi, P., Femminella, G.D., Liccardo, D., Zincarelli, C., de Lucia, C.,
Pagano, G., Marsico, F., Lymperopoulos, A., Leosco, D. Targeting the β-Adrenergic
Receptor System Through G-Protein-Coupled Receptor Kinase 2: A New Paradigm for
Therapy and Prognostic Evaluation in Heart Failure: From Bench to Bedside. Circ. Heart
Fail. 5: 385-391 (2012). Review.
18) Lymperopoulos, A. Beta-arrestin Biased Agonism/Antagonism at Cardiovascular Seven
Transmembrane- spanning Receptors. Curr. Pharm. Des. 18: 192-198 (2012). Invited
review.
19) Lymperopoulos, A., Rengo, G., Koch, W.J. GRK2 Inhibition in Heart Failure: Something Old,
Something New. Curr. Pharm. Des. 18: 186-191 (2012). Invited review.
20) Lymperopoulos, A., Rengo, G., Zincarelli, C., Kim, J., Koch, W.J. Adrenal β−arrestin 1
inhibition in vivo attenuates post-myocardial infarction progression to heart failure and
adverse remodeling via reduction of circulating aldosterone levels. J. Am. Coll. Cardiol. 57:
356-365 (2011)
21) Lymperopoulos, A. GRK2 and β-arrestins in cardiovascular disease: something old,
something new. Am. J. Cardiovasc. Dis. 1: 126-137 (2011). Invited review.
22) Harvey, A.N., Nguyen, K., Lymperopoulos, A. GRK2 and Beta-Arrestins in Cardiovascular
Disease: Established and Emerging Possibilities for Therapeutic Targeting. Curr. Mol.
Pharmacol. 6: 317-326 (2013). Review.
23) Nguyen, K., Kassimatis, T., Lymperopoulos, A. Impaired desensitization of a human
polymorphic alpha2B-adrenergic receptor variant enhances its sympatho-inhibitory
activity in chromaffin cells. Cell Commun. Signal. 9: 5 (2011)
24) Jasmin, J.F., Rengo, G., Lymperopoulos, A., Gupta, R., Eaton, G.J., Quann, K., Gonzales,
D.M., Mercier, I., Koch, W.J., Lisanti, M.P. Caveolin-1 Deficiency Exacerbates Cardiac
Dysfunction and Reduces Survival in Mice with Myocardial Infarction. Am. J. Physiol. Heart
Circ. Physiol. 300: H1274-H1281 (2011)
25) Drosatos, K., Bharadwaj. K.G., Lymperopoulos, A., Ikeda, S., Khan, R., Hu, Y., Agarwal, R.,
Yu, S., Jiang, H., Steinberg, S.F., Blaner, W.S., Koch, W.J., Goldberg, I.J. Cardiomyocyte
lipids impair {beta}-adrenergic receptor function via PKC activation. Am. J. Physiol.
Endocrinol. Metab. 300: E489-E499 (2011)
26) Rengo, G., Lymperopoulos, A., Leosco, D., Koch, W.J. GRK2 as a novel gene therapy target
in heart failure. J. Mol. Cell. Cardiol. 50: 785-792 (2011). Review.
8

A. LYMPEROPOULOS-CV
27) Lymperopoulos, A., Rengo, G., Gao, E., Ebert, S.N., Dorn, G.W. 2nd, Koch, W.J. Reduction
of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure
progression and improves cardiac function after myocardial infarction. J. Biol. Chem. 285:
16378-16386 (2010)
28) Rengo, G., Leosco, D., Zincarelli, C., Marchese, M., Corbi, G., Liccardo, D., Filippelli, A.,
Ferrara, N., Lisanti, M.P., Koch, W.J., Lymperopoulos, A. Adrenal GRK2 lowering is an
underlying mechanism for the beneficial sympathetic effects of exercise training in heart
failure. Am. J. Physiol. Heart Circ. Physiol. 298: H2032-H2038 (2010)
29) Kassimatis, T.I., Nomikos, A., Giannopoulou, I., Lymperopoulos, A., Moutzouris, D.A.,
Varakis, I., Nakopoulou, L. Transcription factor Sp1 expression is upregulated in human
glomerulonephritis: correlation with pSmad2/3 and p300 expression and renal injury. Ren.
Fail. 32: 243-253 (2010)
30) Lymperopoulos, A., Rengo, G., Zincarelli, C., Kim, J., Soltys, S., Koch W.J. An adrenal β-
arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone
production in vitro and in vivo. Proc. Natl. Acad. Sci. USA 106: 5825-5830 (2009)
31) Rengo, G., Lymperopoulos, A., Koch W.J. Future G-protein coupled receptor targets for
treatment of heart failure. Curr. Treat. Options Cardiovasc. Med. 11: 328-338 (2009).
Review.
32) Rengo, G., Lymperopoulos, A., Zincarelli, C., Donniacuo, M., Soltys, S., Rabinowitz, J.E.,
Koch W.J. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy
improves cardiac function and normalizes the neurohormonal axis in chronic heart failure.
Circulation 119: 89-98 (2009)
33) Lymperopoulos, A., Rengo, G., Zincarelli, C., Soltys, S., Koch W.J. Modulation of Adrenal
Catecholamine Secretion by In Vivo Gene Transfer and Manipulation of G Protein-Coupled
Receptor Kinase-2 Activity. Mol. Ther. 16: 302-307 (2008)
34) Lymperopoulos, A., Rengo, G., Koch, W.J. Adrenal adrenoceptors in heart failure: Finetuning
cardiac stimulation. Tr. Mol. Med. 13: 503-511 (2007). Invited review, featured
cover article.
35) Lymperopoulos, A., Rengo, G., Funakoshi, H., Eckhart, A.D., Koch, W.J. Adrenal GRK2
upregulation mediates sympathetic overdrive in heart failure. Nat. Med. 13: 315-323
(2007). Important Note: This journal (“Nature Medicine”) is the top primary research
journal in Medicine (Research and Experimental), with an “Impact Factor” of 27.553 (2008
ISI Journal Citation Reports).
36) Leosco, D., Rengo, G., Iaccarino, G., Filippelli, A., Lymperopoulos, A., Zincarelli, C.,
Fortunato, F., Golino, L., Marchese, M., Esposito, G., Rapacciuolo, A., Rinaldi, B., Ferrara,
N., Koch, W.J., Rengo, F. Exercise training and beta-blocker treatment ameliorate agedependent
impairment of beta-adrenergic receptor signaling and enhance cardiac
9

A. LYMPEROPOULOS-CV
responsiveness to adrenergic stimulation. Am. J. Physiol. Heart Circ. Physiol. 293: H1596-
H1603 (2007)
37) Flordellis, C., Papathanasopoulos, P., Lymperopoulos, A., Matsoukas, J., Paris, H. Emerging
therapeutic approaches multi-targeting receptor tyrosine kinases and g protein-coupled
receptors in cardiovascular disease. Cardiovasc. Hematol. Agents Med. Chem. 5: 133-145
(2007). Review
38) Karkoulias, G., Mastrogianni, O., Ilias, I., Lymperopoulos, A., Taraviras, S., Tsopanoglou, N.,
Sitaras, N., Flordellis, C.S. Alpha 2-adrenergic receptors decrease DNA replication and cell
proliferation and induce neurite outgrowth in transfected rat pheochromocytoma cells.
Ann. N. Y. Acad. Sci. 1088: 335-345 (2006)
39) Lymperopoulos, A., Karkoulias, G., Koch, W.J., Flordellis, C.S. alpha(2)-Adrenergic receptor
subtype-specific activation of NF-kappaB in PC12 cells. Neurosci. Lett. 402: 210-215 (2006)
40) Manolis, A.S., Patsouras, N., Ilias, I., Constantakopoulos, J., Pyriohou, A., Lymperopoulos,
A., Spathas, D.H., Flordellis C.S. Lack of association between alpha2B-adrenergic receptor
polymorphism and risk of restenosis following coronary angioplasty and stent
implantation--preliminary report. Clin. Chem. Lab. Med. 44: 807-812 (2006)
41) Karkoulias, G., Mastrogianni, O., Lymperopoulos, A., Paris, H., Flordellis, C. alpha(2)-
Adrenergic receptors activate MAPK and Akt through a pathway involving arachidonic acid
metabolism by cytochrome P450-dependent epoxygenase, matrix metalloproteinase
activation and subtype-specific transactivation of EGFR. Cell. Signal. 18: 729-739 (2006)
42) Flordellis, C., Paris, H., Karabinis, A., Lymperopoulos, A. Pharmacogenomics of
adrenoceptors. Pharmacogenomics 5: 803-817 (2004). Review
43) Taraviras, S., Olli-Lahdesmaki, T., Lymperopoulos, A., Charitonidou, D., Mavroidis, E.,
Kallio, J., Scheinin, M., Flordellis, C. α 2 -adrenergic receptor subtypes regulate neuronal
differentiation of transfected PC12 cells through MAPK activation. Eur. J. Cell Biol. 81: 363-
374 (2002)
44) Schaak, S., Cayla, C., Lymperopoulos, A., Flordellis, C., Cussac, D., Denis, C., and Paris, H.
Transcriptional down-regulation of the human α 2C -adrenergic receptor by cAMP. Mol.
Pharmacol. 58: 821-827 (2000)
Textbooks-Book Chapters:
1) Lymperopoulos, A., and French, F. Pharmacogenomics of Heart Failure. In Qing
Yan (Editor): Pharmacogenomics in Drug Discovery and Development, 2 nd
Edition, Methods in Molecular Biology-Springer Protocols, UK: Humana Press,
2014, pp. 245-257 (2014)
10

A. LYMPEROPOULOS-CV
2) Lymperopoulos, A., and Bathgate, A. Arrestins in the Cardiovascular System. In
Louis M. Luttrell, editors: The Molecular Biology of Arrestins, Vol. 118, PMBTS,
UK: Academic Press, 2013, pp. 297-334 (2013)
3) Lymperopoulos, A., Rengo, G., Gao, E., Ebert, S.N., Dorn, G.W., and Koch,
W.J. Adrenal-specific G protein-coupled receptor kinase (GRK)-2 deficiency
reduces circulating catecholamine levels and improves cardiac function after
myocardial infarction. In L. Eiden (Editor): Catecholamine Research in the 21st
Century: Abstracts and Graphical Abstracts, 10th International Catecholamine
Symposium 2012, Oxford, UK: Elsevier, 2013, p. 224, Theme H: Catecholamines
in the Periphery (2013)
4) Lymperopoulos, A., and Koch, W.J. Autonomic Pharmacology. In
Pharmacology and Therapeutics: Principles to Practice (1st edn) (Waldman, S.A.
and Terzic, A., eds), Part 1: Principles, Section 3: Systems pharmacology,
Chapter 9: Autonomic Pharmacology, pp. 115-139, Saunders/Elsevier, ISBN: 978-
1-4160-3291-5, Language: English (2009)
5) Lymperopoulos, A., Pairas, G., Scheinin, M., and Flordellis, C. Decreased GRKmediated
Phosphorylation of a Polymorphic α 2B -adrenergic Receptor in PC12
Cells. 3rd HELLENIC FORUM ON BIOACTIVE PEPTIDES, P.A.
Cordopatis, E. Manessi-Zoupa and G. Pairas (Eds.), TYPORAMA, pp. 259-273
(2003)
6) Manolis, A.S., Lymperopoulos, A., Bouga, E.A., Scheinin, M., and Flordellis,
C.S. Significance of G-protein –coupled receptor polymorphisms: The case of α 2 -
adrenergic receptor. Drug Discovery and Design: Medical Aspects, J.Matscoukas
and T. Mavromoustakos (Eds.), IOS Press, Vol. 55: 299-304 (2002)
Published Abstracts:
1) Lymperopoulos, A., Rengo, G., Koch, W.J. Regulation of aldosterone levels by adrenal
βarrestin-1 as a new molecular target in heart failure. J. Heart Disease, Vol. 8, Nr. 1, July
2011, p. 117, Oral Presentation Abstract #467, 16 th World Congress on Heart Disease,
Vancouver, BC, Canada, 23-26 July 2011
2) Lymperopoulos, A., Rengo, G., Magafa, V., Cordopatis, P., Koch, W.J. Biased
Agonism/Antagonism of Sartans and Angiotensin II Analogs for Angiotensin II
Type 1 Receptor-Induced, β-Arrestin-Dependent Aldosterone Production in Heart
Failure. Circ. Suppl. II, Vol. 122, Oral Presentation Abstract #10263, 2010 AHA
Scientific Sessions, Chicago, IL, USA, 13-17 November 2010
3) Jasmin, J.F., Rengo, G., Lymperopoulos, A., Gupta, R., Eaton, G., Quann, K.,
Gonzales, D., Mercier, I., Koch, W.J., Lisanti, M.P. Caveolin-1 Deficiency
Exacerbates Cardiac Dysfunction and Reduces Survival in Mice with Myocardial
Infarction. Circ. Suppl. II, Vol. 122, Poster Presentation Abstract #14567, 2010
AHA Scientific Sessions, Chicago, IL, USA, 13-17 November 2010
11

A. LYMPEROPOULOS-CV
4) Lymperopoulos, A., Rengo, G., Magafa, V., Cordopatis, P., Koch, W.J. Biased
Agonism/Antagonism of β-Arrestin activation by the Angiotensin II Type 1
Receptor: A Study of Sartans and Angiotensin II Analogs Using Aldosterone
Turnover as a Readout. J. Card. Fail. Suppl. 1 August 2010, Vol. 16, No 8, S30-
S31, Abstract #088, 14th HFSA Annual Scientific Meeting, San Diego, CA, USA,
12-15 September 2010
5) Lymperopoulos, A., Rengo, G., Koch, W.J. Biased agonism/antagonism of β-
arrestin activation by the angiotensin II type 1 receptor: a study of sartans and
angiotensin II analogs using aldosterone turnover as a readout. Eur. Heart J.
(2010) 31 (Suppl. 1): 1-296, p. 75, Abstract #P593, ESC Congress 2010,
Stockholm, Sweden, 28 August-1 September 2010
6) Lymperopoulos, A., Rengo, G., Gao, E., Zincarelli, C., Koch, W.J. Genetic
deletion of β-arrestin-1 improves function of the infarcted heart by reducing
cardiac β-adrenergic receptor desensitization and cardiotoxic neurohormonal
overstimulation. Cardiovasc. Res., Vol. 87, Suppl. 1, S92-S93, Oral Presentation
Abstract #302, Frontiers in Cardiovascular Biology Congress of the ESC Council
on Basic Cardiovascular Sciences, Berlin, Germany, 16-19 July 2010
7) Lymperopoulos, A., Rengo, G., Gao, E., Zincarelli, C., Koch, W.J. Genetic
deletion of β-arrestin-1 improves function of the infarcted heart by reducing
cardiac β-adrenergic receptor desensitization and cardiotoxic neurohormonal
overstimulation. Circ. Suppl. II, Vol. 120, S1177, Oral Presentation Abstract
#5935, 2009 AHA Scientific Sessions, Orlando, FL, USA, 14-18 November 2009
8) Rengo, G., Lymperopoulos, A., Zincarelli, C., Femminella, G., Liccardo, D.,
Corbi, G., Fillipelli, A., Ferrara, N., Koch, W.J., Leosco, D. Beta-adrenergic
blockade reduces sympathetic overactivation in heart failure and restores adrenal
GRK2-alpha 2 -adrenergic receptor-catecholamine production axis. Circ. Suppl. II,
Vol. 120, S801, Oral Presentation Abstract #3394, 2009 AHA Scientific Sessions,
Orlando, FL, USA, 14-18 November 2009
9) Zincarelli, C., Rengo, G., Golino, L., Lymperopoulos, A., Altobelli, G., Cimini,
V., Marchese, M., De Lucia, C., Koch, W.J., Leosco, D. Cardiac β 1 -adrenergic
receptor blockade promotes angiogenesis in the post-ischemic failing heart via
activation of VEGF- and Akt-dependent signaling pathways. Circ. Suppl. II, Vol.
120, S1053-S1054, Poster Presentation Abstract #5118, 2009 AHA Scientific
Sessions, Orlando, FL, USA, 14-18 November 2009
10) Lymperopoulos, A., Rengo, G., Gao, E., Koch, W.J. Genetic Deletion of β-
arrestin-1 improves function of the infarcted heart by reducing cardiac β-
adrenergic receptor desensitization and cardiotoxic neurohormonal
overstimulation. J. Card. Fail. Suppl. 1 2009, Vol. 15, No 6, S7, Abstract #016,
13th HFSA Annual Scientific Meeting, August 2009
12

A. LYMPEROPOULOS-CV
11) Lymperopoulos, A., Rengo, G., Zincarelli, C., Kim, J., Soltys, S., Koch, W.J. A
Crucial Role for Adrenal β−Αrrestin 1 in Angiotensin II-Dependent Aldosterone
Production During Post-Myocardial Infarction Heart Failure Progression. Poster
presentation #P106, Basic Cardiovascular Sciences Conference 2009-Molecular
Mechanisms of Cardiovascular Disease, Lake Las Vegas, NV, USA (July 20-23,
2009)
12) Rengo, G., Lymperopoulos, A., Zincarelli, C., Marchese, M., Rengo, A.,
Avallone, A., Filippelli, A., Ferrara, N., Koch, W.J., Leosco, D. Restoration of
adrenal GRK2-mediated catecholamine production is an underlying mechanism
for reduction of sympathetic activation by exercise training in heart failure. Eur.
Heart J. 2009; Vol. 30 (Abstract Supplement): 132, European Society of
Cardiology Congress 2009, Barcelona, Spain (29 August-2 September 2009)
13) Lymperopoulos, A., Rengo, G., Gao, E., Moraca, S.R., Ebert, S.N., Dorn, G.W.
2nd, Koch, W.J. Adrenal-Targeted GRK2 Gene Deletion Ameliorates
Sympathetic Overstimulation and Improves Function of the Failing Heart. Circ.
Suppl. II, Vol. 118, No 18, S360-S361, Abstract #1629, October 28, 2008
14) Lymperopoulos, A., Rengo, G., Gao, E., Moraca, S.R., Ebert, S.N., Dorn, G.W.
2nd, Koch, W.J. Adrenal-Targeted GRK2 Gene Deletion Ameliorates
Sympathetic Overstimulation and Improves Function of the Failing Heart. J. Card.
Fail. Suppl. 2008, Vol. 14, No 6, S34, Abstract #102, 12th HFSA Annual
Scientific Meeting, August 2008
15) Rengo, G., Lymperopoulos, A., Zincarelli, C., Donniacuo, M., Soltys, S.,
Rabinowitz, J.E., Koch W.J. Long-term AAV6-βARKct Myocardial Gene
Therapy Improves Cardiac Function Via Restoration Of β-Adrenergic Receptor
Signaling and Neurohormonal Status of The Failing Heart. Circ. Suppl. II, Vol.
118, No 18, S286, Abstract #339, October 28, 2008
16) Lymperopoulos, A., Rengo, G., Chuprun, J.K., Koch, W.J. Adrenal beta-arrestin
1 mediates angiotensin II-induced aldosterone production in vitro and in vivo.
Circ. Suppl. II, Vol. 116, No 16, II-158, Abstract #815, October 16, 2007
17) Lymperopoulos, A., Rengo, G., Chuprun, J.K., Koch, W.J. Adrenal beta-arrestin
1 mediates physiological production of aldosterone in vivo, J. Card. Fail. Suppl.
2007, Vol. 13, No 6, S102, Abstract #097, 11th HFSA Annual Scientific Meeting,
August 2007
18) Rengo, G., Lymperopoulos, A., Zincarelli, C., Soltys, S., Koch W.J. Modulation
of Catecholamine Secretion by In Vivo Gene Transfer of G Protein-Coupled
Receptor Kinase (GRK) Or A GRK2 Inhibitor Peptide In The Adrenal Gland,
Circ. Suppl. II, Vol. 116, No 16, II-158, Abstract #818, October 16, 2007
13

A. LYMPEROPOULOS-CV
19) Lymperopoulos, A., Funakoshi, H., Shapiro, M., Cohn, H.I., Eckhart, A.D.,
Angelotti, T., Koch, W.J. Adrenal G-protein coupled Receptor Kinase (GRK) 2
activity is a potential novel bio-marker of sympathetic outflow in chronic heart
failure, Circ. Suppl. II, Vol. 114, No 18, II-36, Abstract #318, October 31, 2006
20) Lymperopoulos, A., Pleger. S.T., Eckhart, A.D., Koch, W.J. Adrenal G-protein
Coupled Receptor Kinase 2 Up-regulation Mediates Catecholaminergic
Overstimulation of the Failing Heart. Circ. Suppl. II, Vol. 112, No 17, II-80,
Abstract #468, October 25, 2005
21) Lymperopoulos, A. The impact of GPCR polymorphisms on medicinal
chemistry. Lecture L31, 5th INTERNATIONAL CONFERENCE IN
“MEDICINAL CHEMISTRY: DRUG DISCOVERY AND DESIGN”, Patras,
Greece (2004)
22) Lymperopoulos, A., Pairas, G., Scheinin, M., and Flordellis, C. Impaired
agonist-promoted desensitization of a polymorphic α 2B -adrenergic receptor in
PC12 cells. European Journal of Drug Metabolism and Pharmacokinetics, Vol.
28, Nr. 1: Page 17 (2003)
23) Lymperopoulos, A., Pandeli, E., Karkoulias, G., Mastroyianni, O., Pyriohou, A.,
and Flordellis, C. Epinephrine Induces the Activation of the Transcription Factors
AP-1 and NF-κB in PC12 Cells Transfected with α 2 -Adrenergic Receptors.
Review of Clinical Pharmacology and Pharmacokinetics, Greek Edition 2003, 21:
32-33 (2003)
24) Lymperopoulos, A., Taraviras, S., Mastroyianni, O., Stavropoulou, E.,
Kasimatis, T., and Flordellis, C. Phosphatidylinositol-3 Kinase (PI-3K) Mediates
Epinephrine-Induced Survival and Differentiation of PC12- α 2 Cells. Review of
Clinical Pharmacology and Pharmacokinetics, International Edition, 16: 15 (2002)
25) Lymperopoulos, A., Schaak, S., Charitonidou, D., Cayla, C., Denis, C., Paris, H.,
and Flordellis, C. cAMP down-regulates α2C-adrenergic receptor at the
transcriptional level in HepG2 cells. NATO/FEBS Advanced Study Institute-
International Summer School on «Molecular Mechanisms of Signal
Transduction», Island of Spetsai, Greece. Review of Clinical Pharmacology and
Pharmacokinetics, International Edition, 13: 61 (1999)
Research Financial Support:
1) AHA Scientist Development Grant (SDG) Award (National Center) entitled:
“Role of adrenal beta-arrestin-1 in angiotensin II-induced aldosterone production
in post-infarct heart failure” (Award ID: 09SDG2010138), PI: Dr. Anastasios
Lymperopoulos, Duration: 07/01/2009-06/30/2014, Gross Annual Funding:
77,000 $
14

A. LYMPEROPOULOS-CV
2) AHA Great Rivers (Formerly: Pennsylvania-Delaware) affiliate Post-Doctoral
Research Fellowship, “Role of Adrenal GRKs in Regulation of Sympathetic
Nervous System Activity in Heart Failure”, July 2005-July 2008, Thomas
Jefferson University, Philadelphia, PA. PI: Dr. Walter J. Koch
3) Co-Investigator, “Adrenal GRKs and Adrenergic Signaling in Heart Failure”,
NIH Research Grant: R01 HL085503-01A1, April 2007-July 2009. PI: Dr. Walter
J. Koch
4) Nova Southeastern University`s President's Faculty Research & Development
Grant (PFRDG)-FY 2014 (NSU intramural grant) entitled: “Angiotensin receptor
blockers & beta-arrestin-dependent aldosterone production” (Award ID: PFRDG
335320), PI: Dr. Anastasios Lymperopoulos, Duration: 08/01/2013-07/31/2014,
Total Funding: 9,661 $
5) Nova Southeastern University`s Health Professions Division (HPD) Research
Grant (NSU-HPD intramural grant) entitled: “Role of beta-arrestin-1 in
aldosterone production from adrenocortical cells” (Award ID: 335797-RX-
Lymperopoulos-BetaArrestin1), PI: Dr. Anastasios Lymperopoulos, Duration:
10/01/2011-09/30/2012, Total Funding: 5,000 $
6) Co-Investigator, “Study of Signal Transduction of cloned α 2 -adrenergic receptors
in homologous and heterologous cell lines”. BIOMED II Program, European
Union Research Council, 1998-2001. PI: Dr. Chris S. Flordellis
15